In an effort to combat the coronavirus (COVID-19), front-line physicians are re-purposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.
Topic(s): COVID-19, Ototoxicity, Hydroxychloroquine, Azithromycin
